文献速递细菌感染、耐药与抗菌药物

从药代动力学角度理解已上市抗生素用于口吸入的适宜性:基于利福平、环丙沙星和替加环素体内数据的整合模型研究

Understanding the suitability of established antibiotics for oral inhalation from a pharmacokinetic perspective: an integrated model-based investigation based on rifampicin, ciprofloxacin and tigecycline in vivo data.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

研究建立PBPK/PD模型,在大鼠静脉输注后同步测定肺组织、内皮衬液和全身药物浓度,并转化至人体模拟口吸入治疗支气管感染。结果显示常用吸入药物优化参数主要增加肺选择性而非疗效,低渗透性、高上皮外排比和明显抗生素后效应才是吸入优于全身给药的关键参数。

要点

  • 常用吸入药物优化参数(高全身清除率、低口服生物利用度)主要增加肺选择性,对疗效影响小。
  • 低渗透性、高上皮外排比和明显抗生素后效应是提示吸入优于全身给药的最重要参数。
  • PBPK/PD模型能描述大鼠肺内药代动力学,并已转化至人体适配吸入给药。

核心结论

  • 本研究可能有助于开发提供高肺浓度、快速暴露起始并伴随较低全身药物浓度的口吸入抗生素。

研究设计与样本

  • 建立基于生理的药代动力学/药效学(PBPK/PD)模型,在大鼠静脉输注后同步测定所有药物的肺组织、内皮衬液和全身体内药物浓度-时间曲线。
  • 利用大鼠数据开发PBPK/PD模型,转化至人体并适配吸入给药,模拟比较口吸入治疗支气管感染的潜在获益,覆盖胞内病原体和存在于支气管上皮衬液中的细菌。
  • 进行示例性敏感性分析,以潜在指导吸入抗生素局部疗效相关的药物优化。

主要发现

  • PBPK/PD模型能够描述大鼠肺内药代动力学。
  • 常用于口吸入药物的优化参数(如高全身清除率和低口服生物利用度)对疗效影响很小,反而主要增加肺选择性。
  • 低渗透性、高上皮外排比和明显的抗生素后效应是提示吸入优于全身给药用于局部作用抗生素的最有影响力参数。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treating pulmonary infections by administering drugs via oral inhalation represents an attractive alternative to usual routes of administration. However, the local concentrations after inhalation are typically not known and the presumed benefits are derived from experiences with drugs specifically optimized for inhaled administration. OBJECTIVES: A physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model was developed to elucidate the pulmonary PK for ciprofloxacin, rifampicin and tigecycline and link it to bacterial PK/PD models. An exemplary sensitivity analysis was performed to potentially guide drug optimization regarding local efficacy for inhaled antibiotics. METHODS: Detailed pulmonary tissue, endothelial lining fluid and systemic in vivo drug concentration-time profiles were simultaneously measured for all drugs in rats after intravenous infusion. Using this data, a PBPK/PD model was developed, translated to humans and adapted for inhalation. Simulations were performed comparing potential benefits of oral inhalation for treating bronchial infections, covering intracellular pathogens and bacteria residing in the bronchial epithelial lining fluid. RESULTS: The PBPK/PD model was able to describe pulmonary PK in rats. Often applied optimization parameters for orally inhaled drugs (e.g. high systemic clearance and low oral bioavailability) showed little influence on efficacy and instead mainly increased pulmonary selectivity. Instead, low permeability, a high epithelial efflux ratio and a pronounced post-antibiotic effect represented the most impactful parameters to suggest a benefit of inhalation over systemic administration for locally acting antibiotics. CONCLUSIONS: The present work might help to develop antibiotics for oral inhalation providing high pulmonary concentrations and fast onset of exposure coupled with lower systemic drug concentrations.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Himstedt A, Braun C, Wicha SG, et al. Understanding the suitability of established antibiotics for oral inhalation from a pharmacokinetic perspective: an integrated model-based investigation based on rifampicin, ciprofloxacin and tigecycline in vivo data. J Antimicrob Chemother. 2022. PMID: 35904005. doi:10.1093/jac/dkac240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。